New combo therapy aims to outsmart resistant melanoma
NCT ID NCT04562129
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 27 times
Summary
This study is for people with advanced melanoma (stage III or IV that cannot be removed by surgery) whose cancer has stopped responding to standard immunotherapy drugs like nivolumab or pembrolizumab. The trial tests a new sequence of three drugs: high-dose interleukin-2 (IL2) plus low-dose ipilimumab, followed by nivolumab. The goal is to see if this combination can shrink tumors and keep the cancer under control. About 29 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA STAGE III are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.